ClinConnect ClinConnect Logo
Search / Trial NCT04062630

SI Joint Stabilization in Long Fusion to the Pelvis

Launched by SI-BONE, INC. · Aug 19, 2019

Trial Information

Current as of May 07, 2025

Completed

Keywords

Adult Scoliotic Spinal Deformity Sacroiliac Joint Pain Multilevel Lumbar Surgery Si Joint Pain

ClinConnect Summary

This is a multicenter randomized controlled, postmarket clinical study to determine the differences between subjects undergoing standard MLF surgery with S2AI fixation in the pelvis vs the additional placement of iFuse 3-D in the bedrock configuration during MLF surgery. Subjects will be monitored for sacroiliac (SI) joint pain and at two years post surgery a CT scan will be taken to assess S2AI screw loosening or any other findings.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • 1. Age 21-75 at time of screening
  • 2. Patient scheduled for multilevel (\>3 levels) spinal fusion surgery with planned fixation to the pelvis using S2AI screws
  • 3. Patient has signed study-specific informed consent form
  • 4. Patient has the necessary mental capacity to participate and is physically able to comply with study protocol requirements
  • Exclusion Criteria:
  • 1. Indication for multilevel spine fusion surgery is any of the following:
  • 1. Congenital neuromuscular disease
  • 2. Prior pelvic fixation (i.e., patient already has S2AI or iliac bolts in place, current surgery indicated to revise this hardware)
  • 3. Grade IV spondylolisthesis
  • 2. Prior sacroiliac joint fusion/fixation on either side
  • 3. Presence of spinal cord stimulator
  • 4. Presence of severe hip pain that could impair functional and quality of life improvement from complex spine surgery
  • 5. Surgeon plans to use iliac screw for pelvic fixation
  • 6. Any known sacral or iliac pathology
  • 7. Any condition or anatomy that makes treatment with the iFuse Implant System infeasible
  • 8. Known metabolic bone disease
  • 9. Severe osteoporosis
  • 10. Known allergy to titanium or titanium alloys
  • 11. Use of medications known to have detrimental effects on bone quality and soft-tissue healing
  • 12. Neurologic condition that would interfere with postoperative physical therapy
  • 13. Current local or systemic infection that raises the risk of surgery
  • 14. Patient currently receiving or seeking short- or long-term worker's compensation and/or currently involved in injury litigation related to the SI joint or low back pain.
  • 15. Currently pregnant or planning pregnancy in the next 2 years
  • 16. Prisoner or a ward of the state.
  • 17. Known or suspected drug or alcohol abuse
  • 18. Uncontrolled psychiatric disease that could interfere with study participation
  • 19. Fibromyalgia

About Si Bone, Inc.

si-bone, Inc. is a leading medical device company specializing in innovative solutions for sacroiliac joint disorders. Focused on enhancing patient outcomes through advanced technology, si-bone develops and commercializes minimally invasive surgical products designed to alleviate chronic pain and improve mobility. With a commitment to clinical research and evidence-based practices, the company strives to provide orthopedic surgeons with effective tools that address the unmet needs of patients suffering from sacroiliac joint dysfunction. si-bone’s dedication to quality, safety, and innovation positions it at the forefront of the evolving landscape of orthopedic care.

Locations

Rochester, Minnesota, United States

La Jolla, California, United States

Ann Arbor, Michigan, United States

Columbus, Ohio, United States

Little Rock, Arkansas, United States

Royal Oak, Michigan, United States

Chicago, Illinois, United States

Phoenix, Arizona, United States

Minneapolis, Minnesota, United States

Aurora, Colorado, United States

Plano, Texas, United States

Fort Wayne, Indiana, United States

Richmond, Victoria, Australia

Charlotte, North Carolina, United States

San Francisco, California, United States

Buffalo, New York, United States

Magdeburg, , Germany

Seattle, Washington, United States

Stanmore, , United Kingdom

La Jolla, California, United States

Los Angeles, California, United States

Orlando, Florida, United States

Coeur D'alene, Idaho, United States

New York, New York, United States

Nashville, Tennessee, United States

Austin, Texas, United States

Fort Worth, Texas, United States

Charlottesville, Virginia, United States

Charlottesville, Virginia, United States

Richmond, Virginia, United States

Legnano, Milan, Italy

Patients applied

0 patients applied

Trial Officials

Daniel Cher, MD

Study Director

SI-BONE

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials